Sir,

We read with interest the editorial on a possible role for ketamine in suicide prevention in emergency and mainstream psychiatry.\[[@ref1]\] The editorial cited a meta-analysis\[[@ref2]\] that included five studies. One of these five studies\[[@ref3]\] used a single question from the Montgomery--Asberg Depression Rating Scale to assess change in suicidal ideation; the rest, in contrast, used a separate suicidal ideation scale. More importantly, this study\[[@ref3]\] was retracted in July 2017\[[@ref4]\] because it supposedly misrepresented both the protocol-specified doses and the actual-delivered doses of ketamine in the study.

We wonder how much the findings of the meta-analysis\[[@ref2]\] would change were the retracted data\[[@ref3]\] to be removed; and whether the message in the editorial would be moderated, in consequence.
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